| Name | Title | Contact Details |
|---|
Our approach consists of four primary factors: 1. Provide a personalized experience with every customer interaction. 2. Offer products with inherent value that address unique customer needs. 3. Locally owned and operated. 4. Loans deployed to assist local businesses and residents. Member FDIC. Equal Housing Lender.
EverZinc is a global leader in producing specialty zinc materials, with a history of over 185 years. Established in 2016, the company became the worlds largest zinc specialty chemical producer after merging with U.S. Zinc in 2022. Headquartered in Houston, Texas, EverZinc operates 14 production sites across North America, Europe, and Asia, employing over 800 people. The company specializes in four main product lines: fine zinc powders, zinc oxide, zinc powders for batteries, and Zano®, an ultra-fine zinc oxide. These products serve various industries, including personal care, pharmaceuticals, chemicals, textiles, agriculture, paints, coatings, and rubber. EverZincs advanced manufacturing technologies and focus on material science support its diverse customer base and contribute to its strong growth in the zinc specialty chemical market.
Techmotive is a tech-enabled service provider established in 2012, based in Oahu, Hawaii. Our company specializes in re-calibrating Advanced Driver Assistance Systems (ADAS) for vehicles, primarily for collision centers. ADAS are systems within vehicles that assist drivers with driving and parking, enhancing safety and overall driving experience by using sensors, cameras, and software algorithms to monitor surroundings, detect potential hazards, and alert or take corrective actions as needed. With a heritage built on innovation, quality, and trust, Techmotive stands as a leader in the automotive service industry. We invite you to explore our services and experience the difference that Original Equipment (OE) and dedication to excellence can make.
Fleetworx help the car fleet supply chain work better for everyone. We do this by combining data analytics with technology and expertise. Our specialist services help businesses deliver robust company car fleet management in the UK and across EMEA. We leverage data analytics to dramatically improve decision making and our expertise and practical influence spans the entire fleet supply chain. Our primary objective is to deliver savings, compliance and control and our focused and impartial approach is proven to deliver a significant return on investment. Savings - we provide client-side support in the design and delivery of cost-saving and carbon-saving company car policies. Compliance - we act as an extension of your business. Our robust Management Information System, Fleetworx Centrax, ensure you and your supply chain is fully compliant. Control - we impose tight control on all aspects of your company car fleet, creating a slick, cost-effective and valued reward and retention solution. Our services are particularly valued by fleet generalists in HR/procurement or finance roles who have company car fleet responsibility Contact us at sales@fleetworx.com or visit our website to read our thoughts on the fleet sector and learn more about how we help our clients.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.